INTERCEPT PHARMACEUTICALS, INC. Insider Trading for October 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for October 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 11,100 | |
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 223.65 | 391 | 87,447 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 31.90 | 1,000 | 31,900 | 15,875 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,299 | 0 | 6,490 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 234.87 | 100 | 23,487 | 16,107 | 16.2 K to 16.1 K (-0.62 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 232.92 | 900 | 209,632 | 16,207 | 17.1 K to 16.2 K (-5.26 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 31.90 | 1,000 | 31,900 | 17,107 | 16.1 K to 17.1 K (+6.21 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,299 | 0 | 16,107 | 14.8 K to 16.1 K (+8.77 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 14,703 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 8,113 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 233.97 | 832 | 194,664 | 14,855 | 15.7 K to 14.9 K (-5.30 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 234.01 | 500 | 117,005 | 15,687 | 16.2 K to 15.7 K (-3.09 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 232.97 | 1,000 | 232,965 | 16,187 | 17.2 K to 16.2 K (-5.82 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 232.24 | 1,500 | 348,358 | 17,187 | 18.7 K to 17.2 K (-8.03 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 227.69 | 688 | 156,651 | 18,687 | 19.4 K to 18.7 K (-3.55 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 226.30 | 500 | 113,151 | 19,375 | 19.9 K to 19.4 K (-2.52 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 19,875 | 15.9 K to 19.9 K (+25.20 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 15,875 | 14.3 K to 15.9 K (+11.38 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 3,245 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 8,762 | 8.1 K to 8.8 K (+8.00 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 156,628 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,867 | 0 | 24,339 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 234.94 | 200 | 46,987 | 479,909 | 480.1 K to 479.9 K (-0.04 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 233.74 | 100 | 23,374 | 480,109 | 480.2 K to 480.1 K (-0.02 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 232.15 | 300 | 69,645 | 480,209 | 480.5 K to 480.2 K (-0.06 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 231.31 | 700 | 161,920 | 480,509 | 481.2 K to 480.5 K (-0.15 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 230.30 | 600 | 138,181 | 481,209 | 481.8 K to 481.2 K (-0.12 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 229.30 | 1,750 | 401,272 | 481,809 | 483.6 K to 481.8 K (-0.36 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 228.45 | 3,500 | 799,579 | 483,559 | 487.1 K to 483.6 K (-0.72 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 227.64 | 1,450 | 330,082 | 487,059 | 488.5 K to 487.1 K (-0.30 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 226.53 | 1,400 | 317,147 | 488,509 | 489.9 K to 488.5 K (-0.29 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 489,909 | 479.9 K to 489.9 K (+2.08 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,867 | 0 | 479,909 | 475 K to 479.9 K (+1.02 %) |